Welcome to our dedicated page for Teleflex SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
Teleflex Inc. executive Daniel V. Logue reported a tax-related share disposition. On the vesting of restricted and performance stock units, 484 shares of common stock were withheld to satisfy tax liabilities at a price of $122.06 per share. After this withholding, he holds 14,930.888 shares directly and 305.683 shares indirectly through a 401(k) trustee.
Teleflex Inc. corporate vice president of manufacturing and supply James Winters reported a Form 4 showing a tax-withholding disposition of 661 shares of common stock at $122.06 per share. The shares were withheld to satisfy tax liabilities on vested restricted and performance stock units, and Winters now directly holds 5,000 shares.
Teleflex Incorporated outlines a major strategic shift in this annual report. The company, a global provider of single-use medical devices for critical care and surgical applications, plans to sell its Acute Care, Interventional Urology and OEM businesses for $2.0 billion in cash, with approximately $1.5 billion expected for OEM and $530 million for Acute Care and IU. These transactions are subject to regulatory approvals and are targeted for completion in the second half of 2026.
After these divestitures, Teleflex will focus on vascular, emergency, interventional and surgical product lines across its Americas, EMEA and Asia segments. The company continues multi‑year footprint realignment and restructuring programs aimed at improving manufacturing and cost efficiency, and is upgrading its global ERP system.
Governance changes include the January 2026 departure of Chairman, President and CEO Liam J. Kelly and the appointment of director Stuart A. Randle as Interim President and CEO, with Stephen K. Klasko, M.D. becoming independent Chair. The filing also details extensive regulatory exposure, reimbursement pressures, intense competition, reliance on ethylene oxide sterilization, and execution risks around the strategic transformation.
Teleflex reported strong 2025 results from continuing operations while outlining a major portfolio transformation and restructuring tied to pending business divestitures. GAAP revenue from continuing operations was $1,992.7 million, up 17.2%, and adjusted revenue reached $1,983.7 million, up 16.3%.
GAAP diluted EPS from continuing operations was $1.31, while adjusted diluted EPS rose to $6.98 from $6.42, reflecting higher revenue, improved operating income and a lower tax rate, partly offset by increased interest expense and foreign exchange headwinds. Second-half 2025 pro forma adjusted constant currency revenue grew 4.7%, helped by contribution from the acquired Vascular Intervention business.
For 2026, the company guides GAAP revenue growth of 14.4%–15.4% and pro forma adjusted constant currency revenue growth of 4.5%–5.5%. GAAP EPS from continuing operations is expected at $2.90–$3.20, with adjusted EPS of $6.25–$6.55, reflecting about $90 million of stranded costs after reclassifying divested units as discontinued operations.
In connection with its planned divestitures of the Acute Care, Interventional Urology and OEM businesses, Teleflex’s board approved a multi‑year restructuring plan. The company expects $31–$37 million in restructuring and related charges, mostly cash, and annual pre‑tax savings of $48–$52 million once actions are substantially completed by mid‑2028.
Teleflex reported strong 2025 results from continuing operations while outlining a major portfolio transformation and restructuring tied to pending business divestitures. GAAP revenue from continuing operations was $1,992.7 million, up 17.2%, and adjusted revenue reached $1,983.7 million, up 16.3%.
GAAP diluted EPS from continuing operations was $1.31, while adjusted diluted EPS rose to $6.98 from $6.42, reflecting higher revenue, improved operating income and a lower tax rate, partly offset by increased interest expense and foreign exchange headwinds. Second-half 2025 pro forma adjusted constant currency revenue grew 4.7%, helped by contribution from the acquired Vascular Intervention business.
For 2026, the company guides GAAP revenue growth of 14.4%–15.4% and pro forma adjusted constant currency revenue growth of 4.5%–5.5%. GAAP EPS from continuing operations is expected at $2.90–$3.20, with adjusted EPS of $6.25–$6.55, reflecting about $90 million of stranded costs after reclassifying divested units as discontinued operations.
In connection with its planned divestitures of the Acute Care, Interventional Urology and OEM businesses, Teleflex’s board approved a multi‑year restructuring plan. The company expects $31–$37 million in restructuring and related charges, mostly cash, and annual pre‑tax savings of $48–$52 million once actions are substantially completed by mid‑2028.
Teleflex corporate VP and Chief HR Officer Cameron P. Hicks received an equity award linked to performance. He acquired 352 shares of common stock underlying performance stock units after performance conditions were met on February 23, 2026, and these units remain subject to vesting on February 28, 2026. After this award, he directly holds 11,759.6473 common shares and indirectly holds 36.0230 shares through a 401(k) trustee.
TELEFLEX INC executive Daniel V. Logue, CVP, General Counsel & Secretary, acquired 443 shares of common stock on a grant/award basis at no cost. The shares relate to performance stock units whose conditions were determined satisfied on February 23, 2026 and remain subject to vesting on February 28, 2026. Following this award, he holds 15,414.888 shares directly and 300.876 shares indirectly through a 401(k) trustee.
Winters James reported acquisition or exercise transactions in this Form 4 filing.
Teleflex Inc. corporate vice president James Winters reported an equity award of 354 shares of common stock. The award reflects performance stock units whose performance conditions were determined to be satisfied on February 23, 2026 and that are payable solely in shares.
These units remain subject to vesting on February 28, 2026, meaning Winters does not fully own them until that date. After this award, his directly held common stock reported in this filing totals 5,661 shares.
Deren John reported acquisition or exercise transactions in this Form 4 filing.
Teleflex Executive Vice President & CFO John Deren reported an equity award of 161 shares of common stock on February 23, 2026, at $0.00 per share, from performance stock units whose conditions were satisfied. These units remain subject to vesting on February 28, 2026. After the award, Deren directly holds 4,749 common shares, with an additional 4.308 shares held indirectly through a 401(k) trustee.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report a passive ownership stake in Teleflex Inc. They beneficially own 1,923,208 shares of Teleflex common stock, representing 4.35% of the class as of 12/31/2025.
The firms hold shared voting and shared dispositive power over all reported shares, with no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Teleflex.
Morgan Stanley and Atlanta Capital have reduced their holdings in Teleflex Inc. common stock to below 5% each. As of the report date, Morgan Stanley reports beneficial ownership of 2,162,407 shares, representing 4.9% of the class, while Atlanta Capital reports 1,911,845 shares, or 4.3%.
Both firms report only shared voting and dispositive power over these shares and state that the securities were acquired and are held in the ordinary course of business, not to change or influence control of Teleflex.